

Jordan Feld

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8445079/publications.pdf>

Version: 2024-02-01

354
papers

20,795
citations

10373

72
h-index

11928

134
g-index

373
all docs

373
docs citations

373
times ranked

18129
citing authors

#	ARTICLE	IF	CITATIONS
1	Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 2584.	3.8	1,327
2	Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options. <i>New England Journal of Medicine</i> , 2013, 368, 1867-1877.	13.9	992
3	Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. <i>New England Journal of Medicine</i> , 2015, 373, 2599-2607.	13.9	945
4	Mechanism of action of interferon and ribavirin in treatment of hepatitis C. <i>Nature</i> , 2005, 436, 967-972.	13.7	878
5	Treatment of HCV with ABT-450/râ€“Ombitasvir and Dasabuvir with Ribavirin. <i>New England Journal of Medicine</i> , 2014, 370, 1594-1603.	13.9	816
6	Residual NADPH Oxidase and Survival in Chronic Granulomatous Disease. <i>New England Journal of Medicine</i> , 2010, 363, 2600-2610.	13.9	482
7	Hepatic Gene Expression Discriminates Responders and Nonresponders in Treatment of Chronic Hepatitis C Viral Infection. <i>Gastroenterology</i> , 2005, 128, 1437-1444.	0.6	433
8	Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 135-184.	3.7	370
9	Glecaprevirâ€“Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. <i>New England Journal of Medicine</i> , 2018, 378, 354-369.	13.9	361
10	Autoimmune hepatitis: Effect of symptoms and cirrhosis on natural history and outcome. <i>Hepatology</i> , 2005, 42, 53-62.	3.6	308
11	Extrahepatic Morbidity and Mortality of Chronic Hepatitis C. <i>Gastroenterology</i> , 2015, 149, 1345-1360.	0.6	306
12	From non-A, non-B hepatitis to hepatitis C virus cure. <i>Journal of Hepatology</i> , 2015, 62, S87-S99.	1.8	284
13	Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores. <i>Gastroenterology</i> , 2019, 157, 1264-1278.e4.	0.6	252
14	Clinical trial: pilot study of metformin for the treatment of nonâ€“alcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 29, 172-182.	1.9	249
15	Increased caffeine consumption is associated with reduced hepatic fibrosis. <i>Hepatology</i> , 2010, 51, 201-209.	3.6	245
16	Natural Killer Cells Are Polarized Toward Cytotoxicity in Chronic Hepatitis C in an Interferon-Alphaâ€“Dependent Manner. <i>Gastroenterology</i> , 2010, 138, 325-335.e2.	0.6	243
17	Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. <i>Hepatology</i> , 2007, 46, 1548-1563.	3.6	242
18	Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. <i>Hepatology</i> , 2015, 62, 79-86.	3.6	232

#	ARTICLE	IF	CITATIONS
19	Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 153-161.	3.7	231
20	Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. <i>Journal of Hepatology</i> , 2017, 66, 485-493.	1.8	225
21	Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials. <i>Gastroenterology</i> , 2017, 153, 113-122.	0.6	215
22	Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. <i>Journal of Hepatology</i> , 2020, 72, 539-557.	1.8	208
23	Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 498-510.	5.2	180
24	Hepatitis B Virus-Specific and Global T-Cell Dysfunction in Chronic Hepatitis B. <i>Gastroenterology</i> , 2016, 150, 684-695.e5.	0.6	178
25	Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection. <i>Gastroenterology</i> , 2016, 150, 419-429.	0.6	166
26	Recommendations for the management of hepatitis C virus infection among people who inject drugs. <i>International Journal of Drug Policy</i> , 2015, 26, 1028-1038.	1.6	159
27	Integrated Quantum Dot Barcode Smartphone Optical Device for Wireless Multiplexed Diagnosis of Infected Patients. <i>ACS Nano</i> , 2015, 9, 3060-3074.	7.3	157
28	American Society of Clinical Oncology Provisional Clinical Opinion: Chronic Hepatitis B Virus Infection Screening in Patients Receiving Cytotoxic Chemotherapy for Treatment of Malignant Diseases. <i>Journal of Clinical Oncology</i> , 2010, 28, 3199-3202.	0.8	153
29	Hepatitis B Virus Screening for Patients With Cancer Before Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update. <i>Journal of Clinical Oncology</i> , 2015, 33, 2212-2220.	0.8	149
30	What Are the Benefits of a Sustained Virologic Response to Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection?. <i>Gastroenterology</i> , 2019, 156, 446-460.e2.	0.6	149
31	Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks. <i>Journal of Hepatology</i> , 2016, 64, 301-307.	1.8	147
32	Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 338-351.	8.2	144
33	The phenylpropanamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging. <i>Antiviral Research</i> , 2007, 76, 168-177.	1.9	141
34	Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. <i>Hepatology</i> , 2011, 53, 32-41.	3.6	140
35	Early Changes in Natural Killer Cell Function Indicate Virologic Response to Interferon Therapy for Hepatitis C. <i>Gastroenterology</i> , 2011, 141, 1231-1239.e2.	0.6	139
36	Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis. <i>Hepatology</i> , 2008, 48, 550-556.	3.6	137

#	ARTICLE	IF	CITATIONS
37	Hepatitis C Virus Therapeutic Development: In Pursuit of "Perfectovir". <i>Clinical Infectious Diseases</i> , 2015, 60, 1829-1836.	2.9	134
38	Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2019, 157, 1253-1263.e2.	0.6	131
39	Nonalcoholic Steatohepatitis Is Associated With Liver-Related Outcomes and All-Cause Mortality in Chronic Hepatitis B. <i>Hepatology</i> , 2020, 71, 539-548.	3.6	128
40	Toronto HCC risk index: A validated scoring system to predict 10-year risk of HCC in patients with cirrhosis. <i>Journal of Hepatology</i> , 2018, 68, 92-99.	1.8	126
41	Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study. <i>Gastroenterology</i> , 2019, 156, 1683-1692.e1.	0.6	121
42	Hepatitis C point-of-care diagnostics: in search of a single visit diagnosis. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 1109-1115.	1.5	116
43	Immigration and viral hepatitis. <i>Journal of Hepatology</i> , 2015, 63, 515-522.	1.8	114
44	Combined ursodeoxycholic acid (<scp>UDCA</scp>) and fenofibrate in primary biliary cholangitis patients with incomplete <scp>UDCA</scp> response may improve outcomes. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 283-293.	1.9	109
45	Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study). <i>Gut</i> , 2019, 68, 2206-2213.	6.1	109
46	Ribavirin Improves Early Responses to Peginterferon Through Improved Interferon Signaling. <i>Gastroenterology</i> , 2010, 139, 154-162.e4.	0.6	108
47	Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis. <i>Journal of Viral Hepatitis</i> , 2015, 22, 842-849.	1.0	107
48	Clinical Validation of Quantum Dot Barcode Diagnostic Technology. <i>ACS Nano</i> , 2016, 10, 4742-4753.	7.3	107
49	Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients. <i>Hepatology</i> , 2012, 55, 39-48.	3.6	103
50	Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial. <i>Journal of Hepatology</i> , 2016, 65, 33-39.	1.8	103
51	Hepatic abnormalities in patients with chronic granulomatous disease. <i>Hepatology</i> , 2007, 45, 675-683.	3.6	102
52	An Update on the Management of Chronic Hepatitis C: Consensus Guidelines from the Canadian Association for the Study of the Liver. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2012, 26, 359-375.	1.8	101
53	Defective Hepatic Response to Interferon and Activation of Suppressor of Cytokine Signaling 3 in Chronic Hepatitis C. <i>Gastroenterology</i> , 2007, 132, 733-744.	0.6	100
54	Cell-Type Specific Gene Expression Signature in Liver Underlies Response to Interferon Therapy in Chronic Hepatitis C Infection. <i>Gastroenterology</i> , 2010, 138, 1123-1133.e3.	0.6	99

#	ARTICLE	IF	CITATIONS
55	Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update. <i>Journal of Clinical Oncology</i> , 2020, 38, 3698-3715.	0.8	99
56	Prevalence, Correlates, and Viral Dynamics of Hepatitis Delta among Injection Drug Users. <i>Journal of Infectious Diseases</i> , 2010, 202, 845-852.	1.9	96
57	Hepatitis B Virus Screening Before Chemotherapy for Lymphoma: A Cost-Effectiveness Analysis. <i>Journal of Clinical Oncology</i> , 2012, 30, 3167-3173.	0.8	94
58	Efficacy and Safety of Direct Acting Antivirals for the Treatment of Mixed Cryoglobulinemia. <i>American Journal of Gastroenterology</i> , 2017, 112, 1298-1308.	0.2	93
59	The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver. <i>Cmaj</i> , 2018, 190, E677-E687.	0.9	93
60	Characteristics of Adults in the Hepatitis B Research Network in North America Reflect Their Country of Origin and Hepatitis B Virus Genotype. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 183-192.	2.4	90
61	Epidemiology of autoimmune liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2003, 18, 1118-1128.	1.4	89
62	Life Expectancy in Patients With Chronic HCV Infection and Cirrhosis Compared With a General Population. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1927.	3.8	89
63	Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 867-876.	1.9	88
64	Prevention of viral transmission during lung transplantation with hepatitis C-viraemic donors: an open-label, single-centre, pilot trial. <i>Lancet Respiratory Medicine</i> , 2020, 8, 192-201.	5.2	87
65	Inactivating hepatitis C virus in donor lungs using light therapies during normothermic ex vivo lung perfusion. <i>Nature Communications</i> , 2019, 10, 481.	5.8	86
66	Hepatic Involvement and Portal Hypertension Predict Mortality in Chronic Granulomatous Disease. <i>Gastroenterology</i> , 2008, 134, 1917-1926.	0.6	84
67	Hepatitis C " identifying patients with progressive liver injury. <i>Hepatology</i> , 2006, 43, S194-S206.	3.6	82
68	Identifying cirrhosis, decompensated cirrhosis and hepatocellular carcinoma in health administrative data: A validation study. <i>PLoS ONE</i> , 2018, 13, e0201120.	1.1	82
69	Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1840-1849.e16.	2.4	82
70	Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials. <i>Clinical Infectious Diseases</i> , 2016, 63, 1479-1481.	2.9	81
71	Progress towards hepatitis C virus elimination in high-income countries: An updated analysis. <i>Liver International</i> , 2021, 41, 456-463.	1.9	81
72	Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection. <i>Liver International</i> , 2017, 37, 5-18.	1.9	76

#	ARTICLE	IF	CITATIONS
73	Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 649-657.	3.7	76
74	Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study. <i>CMAJ Open</i> , 2016, 4, E605-E614.	1.1	74
75	Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. <i>American Journal of Gastroenterology</i> , 2020, 115, 1066-1074.	0.2	74
76	Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 421-430.e6.	2.4	72
77	Hepatitis B virus DNA prediction rules for hepatitis B e antigenâ€“negative chronic hepatitis B. <i>Hepatology</i> , 2007, 46, 1057-1070.	3.6	71
78	A research agenda for curing chronic hepatitis B virus infection. <i>Hepatology</i> , 2018, 67, 1127-1131.	3.6	70
79	Endpoints of therapy in chronic hepatitis B. <i>Hepatology</i> , 2009, 49, S96-S102.	3.6	68
80	Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity. <i>Journal of Hepatology</i> , 2021, 74, 1053-1063.	1.8	68
81	An Update on the Management of Chronic Hepatitis C: 2015 Consensus Guidelines from the Canadian Association for the Study of the Liver. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2015, 29, 19-34.	0.8	67
82	Inducing Hepatitis C Virus Resistance After Pig Liver Transplantationâ€“A Proof of Concept of Liver Graft Modification Using Warm Ex Vivo Perfusion. <i>American Journal of Transplantation</i> , 2017, 17, 970-978.	2.6	66
83	Cost-effectiveness of screening for hepatitis C in Canada. <i>Cmaj</i> , 2015, 187, E110-E121.	0.9	65
84	Health care costs associated with hepatocellular carcinoma: A population-based study. <i>Hepatology</i> , 2013, 58, 1375-1384.	3.6	64
85	Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 406-417.	3.7	64
86	Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study). <i>Gastroenterology</i> , 2022, 162, 757-771.e4.	0.6	63
87	Reactivation of Hepatitis B With Reappearance of Hepatitis B Surface Antigen After Chemotherapy and Immunosuppression. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 1130-1137.	2.4	62
88	Hepatic Cellâ€“Type Specific Gene Expression Better Predicts HCV Treatment Outcome Than IL28B Genotype. <i>Gastroenterology</i> , 2012, 142, 1122-1131.e1.	0.6	61
89	Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection. <i>Hepatology</i> , 2013, 57, 2124-2134.	3.6	61
90	Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1821-1830.e6.	2.4	61

#	ARTICLE	IF	CITATIONS
91	New therapeutic agents for chronic hepatitis B. <i>Lancet Infectious Diseases</i> , 2016, 16, e10-e21.	4.6	59
92	Acute Spontaneous Tumor Lysis Syndrome in Adenocarcinoma of the Lung. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2000, 23, 491-493.	0.6	58
93	Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study. <i>International Journal of Drug Policy</i> , 2018, 62, 14-23.	1.6	58
94	Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs. <i>International Journal of Drug Policy</i> , 2017, 47, 51-60.	1.6	54
95	Genetic regulation of OAS1 nonsense-mediated decay underlies association with COVID-19 hospitalization in patients of European and African ancestries. <i>Nature Genetics</i> , 2022, 54, 1103-1116.	9.4	54
96	Abnormal Intestinal Permeability in Primary Biliary Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2006, 51, 1607-1613.	1.1	53
97	Clinical Utility of HCV Core Antigen Detection and Quantification in the Diagnosis and Management of Patients with Chronic Hepatitis C Receiving an All-Oral, Interferon-Free Regimen. <i>Antiviral Therapy</i> , 2018, 23, 211-217.	0.6	53
98	Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist Therapy. <i>Clinical Infectious Diseases</i> , 2020, 71, e115-e124.	2.9	53
99	Guidance for Design and Endpoints of Clinical Trials in Chronic Hepatitis B Report From the 2019 EASL AASLD HBV Treatment Endpoints Conference. <i>Hepatology</i> , 2020, 71, 1070-1092.	3.6	52
100	S-Adenosyl Methionine Improves Early Viral Responses and Interferon-Stimulated Gene Induction in Hepatitis C Nonresponders. <i>Gastroenterology</i> , 2011, 140, 830-839.e3.	0.6	51
101	Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C. <i>Gut</i> , 2014, 63, 161-169.	6.1	51
102	The global campaign to eliminate HBV and HCV infection: International Viral Hepatitis Elimination Meeting and core indicators for development towards the 2030 elimination goals. <i>Journal of Virus Eradication</i> , 2019, 5, 60-66.	0.3	49
103	Approaches for simplified HCV diagnostic algorithms. <i>Journal of the International AIDS Society</i> , 2018, 21, e25058.	1.2	47
104	Interferon-Free Strategies with a Nucleoside/Nucleotide Analogue. <i>Seminars in Liver Disease</i> , 2014, 34, 037-046.	1.8	45
105	Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 25-35.	3.7	45
106	Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study. <i>Clinical Infectious Diseases</i> , 2016, 63, 776-783.	2.9	45
107	Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 494-500.	3.7	45
108	New targets and possible new therapeutic approaches in the chemotherapy of chronic hepatitis B. <i>Hepatology</i> , 2003, 38, 545-553.	3.6	44

#	ARTICLE	IF	CITATIONS
109	Long-term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 887-894.	1.9	44
110	Liver injury is associated with mortality in sickle cell disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 912-921.	1.9	44
111	Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1168-1176.	1.4	44
112	Diagnosing Antibiotic Resistance Using Nucleic Acid Enzymes and Gold Nanoparticles. <i>ACS Nano</i> , 2021, 15, 9379-9390.	7.3	44
113	HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 856-864.	3.7	43
114	Noninvasive markers of fibrosis: key concepts for improving accuracy in daily clinical practice. <i>Annals of Hepatology</i> , 2012, 11, 426-439.	0.6	41
115	Hepatitis B Virus RNA as Early Predictor for Response to Pegylated Interferon Alpha in HBeAg-Negative Chronic Hepatitis B. <i>Clinical Infectious Diseases</i> , 2021, 72, 202-211.	2.9	41
116	A Canadian screening program for hepatitis C: Is now the time?. <i>Cmaj</i> , 2013, 185, 1325-1328.	0.9	40
117	Is there sufficient evidence to recommend antiviral therapy in hepatitis C?. <i>Journal of Hepatology</i> , 2014, 60, 191-196.	1.8	40
118	The applicability of hepatocellular carcinoma risk prediction scores in a North American patient population with chronic hepatitis B infection. <i>Gut</i> , 2016, 65, 1347-1358.	6.1	40
119	Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1 and compensated cirrhosis or advanced fibrosis. <i>Liver International</i> , 2018, 38, 443-450.	1.9	40
120	Role of Serologic and Molecular Diagnostic Assays in Identification and Management of Hepatitis C Virus Infection. <i>Journal of Clinical Microbiology</i> , 2016, 54, 265-273.	1.8	38
121	Entecavir and Peginterferon Alfa-2a in Adults With Hepatitis B e Antigen-Positive Immune-Tolerant Chronic Hepatitis B Virus Infection. <i>Hepatology</i> , 2019, 69, 2338-2348.	3.6	37
122	Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy001.	0.4	36
123	Influence of Socioeconomic Status on Survival of Hepatocellular Carcinoma in the Ontario Population; A Population-Based Study, 1990-2009. <i>PLoS ONE</i> , 2012, 7, e40917.	1.1	36
124	Second generation direct-acting antivirals - Do we expect major improvements?. <i>Journal of Hepatology</i> , 2016, 65, S130-S142.	1.8	35
125	Review article: clinical pharmacology of current and investigational hepatitis B virus therapies. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 231-243.	1.9	35
126	The impact of SVR from direct-acting antiviral and interferon-based treatments for HCV on hepatocellular carcinoma risk. <i>Journal of Viral Hepatitis</i> , 2020, 27, 781-793.	1.0	34

#	ARTICLE	IF	CITATIONS
127	The global campaign to eliminate HBV and HCV infection: International Viral Hepatitis Elimination Meeting and core indicators for development towards the 2030 elimination goals. <i>Journal of Virus Eradication</i> , 2019, 5, 60-66.	0.3	34
128	Hepatitis B e Antigen-Positive Chronic Hepatitis B: Natural History and Treatment. <i>Seminars in Liver Disease</i> , 2006, 26, 116-129.	1.8	32
129	No scientific basis to restrict 8 weeks of treatment with ledipasvir/sofosbuvir to patients with hepatitis C virus RNA $\leq 6,000,000$ IU/mL. <i>Hepatology</i> , 2016, 63, 28-30.	3.6	32
130	HCV core antigen as an alternate test to HCV RNA for assessment of virologic responses to all-oral, interferon-free treatment in HCV genotype 1 infected patients. <i>Journal of Virological Methods</i> , 2017, 245, 14-18.	1.0	32
131	How does coffee prevent liver fibrosis? biological plausibility for recent epidemiological observations. <i>Hepatology</i> , 2014, 60, 464-467.	3.6	30
132	Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters. <i>Gut</i> , 2015, 64, 322-331.	6.1	30
133	Lipopolysaccharide and Tumor Necrosis Factor Alpha Inhibit Interferon Signaling in Hepatocytes by Increasing Ubiquitin-Like Protease 18 (USP18) Expression. <i>Journal of Virology</i> , 2016, 90, 5549-5560.	1.5	30
134	Durability of Response After Hepatitis B Surface Antigen Seroclearance During Nucleos(t)ide Analogue Treatment in a Multiethnic Cohort of Chronic Hepatitis B Patients: Results After Treatment Cessation. <i>Clinical Infectious Diseases</i> , 2017, 65, 680-683.	2.9	30
135	Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. <i>Journal of Hepatology</i> , 2020, 72, 431-440.	1.8	30
136	Poor Recognition of Risk Factors for Hepatitis B by Physicians Prescribing Immunosuppressive Therapy: A Call for Universal Rather than Risk-Based Screening. <i>PLoS ONE</i> , 2015, 10, e0120749.	1.1	29
137	Sorting out cirrhosis: mechanisms of non-response to hepatitis C therapy. <i>Liver International</i> , 2015, 35, 1923-1933.	1.9	28
138	Estimating chronic hepatitis C prognosis using transient elastography-based liver stiffness: A systematic review and meta-analysis. <i>Journal of Viral Hepatitis</i> , 2018, 25, 502-513.	1.0	28
139	Association Between Severe Serum Alanine Aminotransferase Flares and Hepatitis B e Antigen Seroconversion and HBV DNA Decrease in Untreated Patients With Chronic HBV Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2541-2551.e2.	2.4	28
140	HCV persistence: Cure is still a four letter word. <i>Hepatology</i> , 2005, 41, 23-25.	3.6	27
141	Virological responses during treatment for recent hepatitis C virus. <i>Aids</i> , 2012, 26, 1653-1661.	1.0	27
142	Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection. <i>Journal of Hepatology</i> , 2021, 75, 829-839.	1.8	27
143	Ribavirin improves the IFN- γ response of natural killer cells to IFN-based therapy of hepatitis C virus infection. <i>Hepatology</i> , 2014, 60, 1160-1169.	3.6	26
144	Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs. <i>Cancer</i> , 2020, 126, 1550-1558.	2.0	26

#	ARTICLE	IF	CITATIONS
145	Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection Among People Who Inject Drugs. <i>Clinical Infectious Diseases</i> , 2021, 72, 1392-1400.	2.9	26
146	Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: A systematic review. <i>Hepatology Communications</i> , 2017, 1, 379-390.	2.0	26
147	Antiviral therapy for hepatitis B virus infections: new targets and technical challenges. <i>Journal of Clinical Virology</i> , 2002, 25, 267-283.	1.6	25
148	Does Antiviral Therapy for Chronic Hepatitis B Reduce the Risk of Hepatocellular Carcinoma?. <i>Seminars in Liver Disease</i> , 2013, 33, 157-166.	1.8	25
149	The beginning of the end: What is the future of interferon therapy for chronic hepatitis C?. <i>Antiviral Research</i> , 2014, 105, 32-38.	1.9	25
150	A Systematic Review and Meta-Analysis of Health Utilities in Patients With Chronic Hepatitis C. <i>Value in Health</i> , 2020, 23, 127-137.	0.1	24
151	Global prevalence of hepatitis C virus in women of childbearing age in 2019: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 169-184.	3.7	24
152	Diagnostic Accuracy of Assays Using Point-of-Care Testing or Dried Blood Spot Samples for the Determination of Hepatitis C Virus RNA: A Systematic Review. <i>Journal of Infectious Diseases</i> , 2022, 226, 1005-1021.	1.9	24
153	Applicability of Hepatitis C Virus RNA Viral Load Thresholds for 8-Week Treatments in Patients With Chronic Hepatitis C Virus Genotype 1 Infection. <i>Clinical Infectious Diseases</i> , 2016, 62, 1228-1234.	2.9	23
154	Model-based projection of health and economic effects of screening for hepatitis C in Canada. <i>CMAJ Open</i> , 2017, 5, E662-E672.	1.1	23
155	Estimation of fibrosis progression rates for chronic hepatitis C: a systematic review and meta-analysis update. <i>BMJ Open</i> , 2019, 9, e027491.	0.8	23
156	Simplification of Care for Chronic Hepatitis C Virus Infection. <i>Seminars in Liver Disease</i> , 2020, 40, 392-402.	1.8	23
157	Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy. <i>Hepatology</i> , 2021, 73, 2124-2140.	3.6	23
158	Flu-like Symptoms and Associated Immunological Response Following Therapy with Botulinum Toxins. <i>Neurotoxicity Research</i> , 2013, 24, 298-306.	1.3	22
159	Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin. <i>Journal of Hepatology</i> , 2015, 62, 294-302.	1.8	22
160	Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study. <i>Clinical Infectious Diseases</i> , 2017, 65, 13-19.	2.9	22
161	Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy. <i>International Journal of Drug Policy</i> , 2018, 62, 94-103.	1.6	22
162	The development and validation of magnetic resonance elastography for fibrosis staging in primary sclerosing cholangitis. <i>European Radiology</i> , 2019, 29, 1039-1047.	2.3	22

#	ARTICLE	IF	CITATIONS
163	Controlled Human Infection Model “Fast Track to HCV Vaccine?. New England Journal of Medicine, 2021, 385, 1235-1240.	13.9	22
164	Defining and grading HBV reactivation. Clinical Liver Disease, 2015, 5, 35-38.	1.0	21
165	Relationship Between Metabolic Syndrome, Alanine Aminotransferase Levels, and Liver Disease Severity in a Multiethnic North American Cohort With Chronic Hepatitis B. Diabetes Care, 2018, 41, 1251-1259.	4.3	21
166	Population-based estimate of hepatitis C virus prevalence in Ontario, Canada. PLoS ONE, 2018, 13, e0191184.	1.1	21
167	Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study. Clinical Infectious Diseases, 2019, 69, 1969-1979.	2.9	21
168	Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis. CMAJ Open, 2017, 5, E97-E108.	1.1	20
169	Efficacy and Safety of Cenicriviroc in Patients With Primary Sclerosing Cholangitis: PERSEUS Study. Hepatology Communications, 2021, 5, 478-490.	2.0	20
170	Randomised clinical trial: the benefit of combination therapy with adefovir and lamivudine for chronic hepatitis B. Alimentary Pharmacology and Therapeutics, 2012, 35, 1027-1035.	1.9	19
171	The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and HCV genotype 1 infection. Journal of Viral Hepatitis, 2014, 21, 568-577.	1.0	19
172	The frequency of acute kidney injury in patients with chronic hepatitis C virus infection treated with sofosbuvir-based regimens. Alimentary Pharmacology and Therapeutics, 2017, 46, 46-55.	1.9	19
173	Hepatitis C Core-Antigen Testing from Dried Blood Spots. Viruses, 2019, 11, 830.	1.5	19
174	Patterns of Drug and Alcohol Use and Injection Equipment Sharing Among People With Recent Injecting Drug Use or Receiving Opioid Agonist Treatment During and Following Hepatitis C Virus Treatment With Direct-acting Antiviral Therapies: An International Study. Clinical Infectious Diseases, 2020, 70, 2369-2376.	2.9	19
175	The emergency department as a setting-specific opportunity for population-based hepatitis C screening: An economic evaluation. Liver International, 2020, 40, 1282-1291.	1.9	19
176	The impact of the first, second and third waves of covid-19 on hepatitis B and C testing in Ontario, Canada. Journal of Viral Hepatitis, 2022, 29, 205-208.	1.0	19
177	Protein Interferon-Stimulated Gene 15 Conjugation Delays but Does Not Overcome Coronavirus Proliferation in a Model of Fulminant Hepatitis. Journal of Virology, 2014, 88, 6195-6204.	1.5	18
178	Effect of thrombocytopenia on treatment tolerability and outcome in patients with chronic HCV infection and advanced hepatic fibrosis. Journal of Hepatology, 2014, 61, 482-491.	1.8	18
179	Race or genetic makeup for hepatitis C virus treatment decisions?. Hepatology, 2017, 65, 2124-2125.	3.6	18
180	Challenges With Stopping Long-term Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B. Gastroenterology, 2020, 158, 1185-1190.	0.6	18

#	ARTICLE	IF	CITATIONS
181	Key Elements on the Pathway to HCV Elimination: Lessons Learned From the AASLD HCV Special Interest Group 2020. <i>Hepatology Communications</i> , 2021, 5, 911-922.	2.0	18
182	Functional Exhaustion of HBV-Specific CD8 T Cells Impedes PD-L1 Blockade Efficacy in Chronic HBV Infection. <i>Frontiers in Immunology</i> , 2021, 12, 648420.	2.2	18
183	Acute Hepatitis C: Management in the Rapidly Evolving World of HCV. <i>Current Gastroenterology Reports</i> , 2014, 16, 371.	1.1	17
184	Treatment of hepatitis B virus with combination therapy now and in the future. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2017, 31, 347-355.	1.0	17
185	Age, race and viral genotype are associated with the prevalence of hepatitis B e antigen in children and adults with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2019, 26, 856-865.	1.0	17
186	Risk stratification in primary sclerosing cholangitis: comparison of biliary stricture severity on MRCP versus liver stiffness by MR elastography and vibration-controlled transient elastography. <i>European Radiology</i> , 2020, 30, 3735-3747.	2.3	17
187	Evaluation of Dried Blood Spot Testing for SARS-CoV-2 Serology Using a Quantitative Commercial Assay. <i>Viruses</i> , 2021, 13, 962.	1.5	17
188	Symptomatic and Pathophysiologic Predictors of Hepatitis C Virus Progression in Pediatric Patients. <i>Pediatric Infectious Disease Journal</i> , 2009, 28, 724-727.	1.1	16
189	Arresting the time-dependent H ₂ O ₂ mediated synthesis of gold nanoparticles for analytical detection and preparative chemistry. <i>Journal of Materials Chemistry B</i> , 2013, 1, 4048.	2.9	16
190	Hepatitis C Virus Diagnostics: The Road to Simplification. <i>Clinical Liver Disease</i> , 2018, 12, 125-129.	1.0	16
191	Prenatal hepatitis B screening, and hepatitis B burden among children, in Ontario: a descriptive study. <i>Cmaj</i> , 2020, 192, E1299-E1305.	0.9	16
192	Direct-Acting Antivirals for Hepatitis C Virus (HCV): The Progress Continues. <i>Current Drug Targets</i> , 2017, 18, 851-862.	1.0	16
193	Is There a Role for Ribavirin in the Era of Hepatitis C Virus Direct-Acting Antivirals?. <i>Gastroenterology</i> , 2012, 142, 1356-1359.	0.6	15
194	The Effectiveness of Ultrasound Surveillance for Hepatocellular Carcinoma in a Canadian Centre and Determinants of Its Success. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2015, 29, 267-273.	0.8	15
195	Psychiatric Care During Hepatitis C Treatment: The Changing Role of Psychiatrists in the Era of Direct-Acting Antivirals. <i>American Journal of Psychiatry</i> , 2015, 172, 512-516.	4.0	15
196	Replication and Oncolytic Activity of an Avian Orthoreovirus in Human Hepatocellular Carcinoma Cells. <i>Viruses</i> , 2017, 9, 90.	1.5	15
197	Influence of hepatitis C viral parameters on pregnancy complications and risk of mother-to-child transmission. <i>Journal of Hepatology</i> , 2022, 77, 1256-1264.	1.8	15
198	Liver stiffness increases acutely during sickle cell vaso-occlusive crisis. <i>American Journal of Hematology</i> , 2013, 88, E250-4.	2.0	14

#	ARTICLE	IF	CITATIONS
199	World Gastroenterology Organisation Global Guideline Hepatitis B. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 691-703.	1.1	14
200	I drink for my liver, Doc: emerging evidence that coffee prevents cirrhosis. <i>F1000Research</i> , 2015, 4, 95.	0.8	14
201	Treatment indication and response to standard of care with peginterferon and ribavirin in acute and chronic HCV infection. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 429-444.	1.0	13
202	I drink for my liver, Doc: emerging evidence that coffee prevents cirrhosis. <i>F1000Research</i> , 2015, 4, 95.	0.8	13
203	Implications of Manganese in Chronic Acquired Hepatocerebral Degeneration. <i>Annals of Hepatology</i> , 2019, 18, 274-278.	0.6	13
204	Restoration of HCV-Specific Immune Responses with Antiviral Therapy: A Case for DAA Treatment in Acute HCV Infection. <i>Cells</i> , 2019, 8, 317.	1.8	13
205	Hepatitis C models of care: approaches to elimination. <i>Canadian Liver Journal</i> , 2020, 3, 165-176.	0.3	13
206	The viral hepatitis B care cascade: A population-based comparison of immigrant groups. <i>Hepatology</i> , 2022, 75, 673-689.	3.6	13
207	What Comes First: Treatment of Viral Hepatitis or Liver Cancer?. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1041-1049.	1.1	12
208	Reducing Read Time of Point-of-Care Test Does Not Affect Detection of Hepatitis C Virus and Reduces Need for Reflex RNA. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1451-1458.e4.	2.4	12
209	Hepatitis B virus screening before adjuvant chemotherapy in patients with early-stage breast cancer: a cost-effectiveness analysis. <i>Breast Cancer Research and Treatment</i> , 2015, 151, 639-652.	1.1	11
210	Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis – A pooled analysis. <i>Journal of Hepatology</i> , 2017, 67, 700-707.	1.8	11
211	Wait Time for Curative Intent Radio Frequency Ablation is Associated with Increased Mortality in Patients with Early Stage Hepatocellular Carcinoma. <i>Annals of Hepatology</i> , 2017, 16, 765-771.	0.6	11
212	Diagnosis of Chronic Hepatitis B Pericomplication: Risk factors and Trends Over Time. <i>Hepatology</i> , 2021, 73, 2141-2154.	3.6	11
213	Precore and Basal Core Promoter Hepatitis B Virus (HBV) Variants Are Present From a Young Age and Differ Across HBV Genotypes. <i>Hepatology</i> , 2021, 73, 1637-1651.	3.6	11
214	Global Utilization Trends of Direct Acting Antivirals (DAAs) during the COVID-19 Pandemic: A Time Series Analysis. <i>Viruses</i> , 2021, 13, 1314.	1.5	11
215	Risk for Hepatocellular Carcinoma After Hepatitis C Virus Antiviral Therapy With Direct-Acting Antivirals: Case Closed?. <i>Gastroenterology</i> , 2017, 153, 890-892.	0.6	11
216	Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines/chemokines during acute hepatitis C virus infection. <i>Virology Journal</i> , 2016, 13, 32.	1.4	10

#	ARTICLE	IF	CITATIONS
217	Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection. <i>Journal of Viral Hepatitis</i> , 2018, 25, 631-639.	1.0	10
218	Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1127-1138.	1.0	10
219	Optimized ex vivo stimulation identifies multi-functional HBV-specific T cells in a majority of chronic hepatitis B patients. <i>Scientific Reports</i> , 2020, 10, 11344.	1.6	10
220	Salvage Therapy with Sofosbuvir/Velpatasvir/Voxilaprevir in DAA-experienced Patients: Results from a Prospective Canadian Registry. <i>Clinical Infectious Diseases</i> , 2021, 72, e799-e805.	2.9	10
221	Report from the International Viral Hepatitis Elimination Meeting (IVHEM), 17-18 November 2017, Amsterdam, the Netherlands: gaps and challenges in the WHO 2030 hepatitis C elimination framework. <i>Journal of Virus Eradication</i> , 2018, 4, 193-195.	0.3	10
222	Death from Liver Failure despite Lamivudine Prophylaxis during R-CHOP Chemotherapy due to Rapid Emergence M204 Mutations. <i>Case Reports in Hepatology</i> , 2013, 2013, 1-5.	0.4	9
223	Plasma Interferon-Gamma-Inducible Protein-10 Levels Are Associated with Early, but Not Sustained Virological Response during Treatment of Acute or Early Chronic HCV Infection. <i>PLoS ONE</i> , 2013, 8, e80003.	1.1	9
224	Hepatitis B Reactivation: The Controversies Continue. <i>Digestive Diseases</i> , 2017, 35, 351-358.	0.8	9
225	Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV-TARGET Analysis. <i>Hepatology Communications</i> , 2019, 3, 1388-1399.	2.0	9
226	Viral hepatitis C cascade of care: A population-level comparison of immigrant and long-term residents. <i>Liver International</i> , 2021, 41, 1775-1788.	1.9	9
227	Low and standard dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine response. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 1018-1027.	1.9	8
228	Optimal preservation of liver biopsy samples for downstream translational applications. <i>Hepatology International</i> , 2013, 7, 758-766.	1.9	8
229	Hepatocellular Carcinoma in a Large Canadian Urban Centre: Stage at Treatment and Its Potential Determinants. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2014, 28, 150-154.	0.8	8
230	Absolute Ligand Discrimination by Dimeric Signaling Receptors. <i>Biophysical Journal</i> , 2016, 111, 917-920.	0.2	8
231	Resistance testing: Interpretation and incorporation into HCV treatment algorithms. <i>Clinical Liver Disease</i> , 2017, 9, 115-120.	1.0	8
232	Time to viral suppression is not related to achievement of SVR12 in HCV GT1-infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin. <i>Journal of Viral Hepatitis</i> , 2017, 24, 280-286.	1.0	8
233	Expert Opinion on Managing Chronic HCV in Patients with Non-Hodgkin Lymphoma and other Extrahepatic Malignancies. <i>Antiviral Therapy</i> , 2018, 23, 23-33.	0.6	8
234	Closing the Stable Door After the Horse Has Bolted: Should We Be Treating People With Immune-Tolerant Chronic Hepatitis B to Prevent Hepatocellular Carcinoma?. <i>Gastroenterology</i> , 2020, 158, 2028-2032.	0.6	8

#	ARTICLE	IF	CITATIONS
235	High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence. <i>American Journal of Gastroenterology</i> , 2021, 116, 1896-1904.	0.2	8
236	The Inflammatory Cytokine Profile Associated With Liver Damage Is Broader and Stronger in Patients With Chronic Hepatitis B Compared to Patients With Acute Hepatitis B. <i>Journal of Infectious Diseases</i> , 2022, 225, 470-475.	1.9	8
237	Hepatitis B virus and hepatitis C virus treatment and management in patients receiving immune-modifying agents. <i>Current Opinion in Rheumatology</i> , 2014, 26, 395-403.	2.0	7
238	Hepatitis B Reactivation With Hepatitis C Treatment: Bringing Some Clarity to the Black Box. <i>Gastroenterology</i> , 2018, 154, 795-798.	0.6	7
239	IL-15 and IFN- β signal through the ERK pathway to inhibit HCV replication, independent of type I IFN signaling. <i>Cytokine</i> , 2019, 124, 154439.	1.4	7
240	Direct-Acting Antivirals for Hepatitis C: Predictors of Early Discontinuation in the Real World. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2019, 25, 697-704.	0.5	7
241	The basis of liver regeneration: A systems biology approach. <i>Annals of Hepatology</i> , 2019, 18, 422-428.	0.6	7
242	A bivalent HCV peptide vaccine elicits pan-genotypic neutralizing antibodies in mice. <i>Vaccine</i> , 2020, 38, 6864-6867.	1.7	7
243	Hepatitis C virus infection characteristics and treatment outcomes in Canadian immigrants. <i>BMC Public Health</i> , 2020, 20, 1345.	1.2	7
244	Remaining challenges in HCV elimination. <i>Journal of Hepatology</i> , 2021, 74, 964-965.	1.8	7
245	Evaluation of Sustained Virologic Response as a Relevant Surrogate Endpoint for Long-term Outcomes of Hepatitis C Virus Infection. <i>Clinical Infectious Diseases</i> , 2021, 72, 780-786.	2.9	7
246	Immunomodulation and RNA interference alter hepatitis B virus-specific CD8 T cell recognition of infected HepG2-TCP. <i>Hepatology</i> , 2022, 75, 1539-1550.	3.6	7
247	Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH). <i>Canadian Liver Journal</i> , 2022, 5, 61-90.	0.3	7
248	Changes in serum hepatitis B surface and e antigen, interferon-inducible protein 10, and aminotransferase levels during combination therapy of immune-tolerant chronic hepatitis B. <i>Hepatology</i> , 2022, 76, 775-787.	3.6	7
249	Feasibility of hepatitis B elimination in high-income countries with ongoing immigration. <i>Journal of Hepatology</i> , 2022, 77, 947-956.	1.8	7
250	Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin. <i>Liver International</i> , 2018, 38, 1571-1575.	1.9	6
251	Hepatitis C: A Canadian perspective. <i>Canadian Liver Journal</i> , 2018, 1, 1-3.	0.3	6
252	The Ubiquitin-Specific Protease 18 Promotes Hepatitis C Virus Production by Increasing Viral Infectivity. <i>Mediators of Inflammation</i> , 2019, 2019, 1-12.	1.4	6

#	ARTICLE	IF	CITATIONS
253	The health impact of delaying direct-acting antiviral treatment for chronic hepatitis C: A decision-analytic approach. <i>Liver International</i> , 2020, 40, 51-59.	1.9	6
254	Peri-complication diagnosis of hepatitis C infection: Risk factors and trends over time. <i>Liver International</i> , 2021, 41, 33-47.	1.9	6
255	Incidence of Hepatitis C Virus Infections Among Users of Human Immunodeficiency Virus Pre-exposure Prophylaxis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 674-681.	2.4	6
256	Hepatitis B e antigen loss in adults and children with chronic hepatitis B living in North America: A prospective cohort study. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1526-1538.	1.0	6
257	Evolution of Therapy for Chronic Hepatitis B: Progressing from the Simple to the Complex. <i>Annals of Internal Medicine</i> , 2007, 147, 806.	2.0	5
258	Hepatitis C RNA assay differences in results: Potential implications for shortened therapy and determination of Sustained Virologic Response. <i>Scientific Reports</i> , 2016, 6, 35410.	1.6	5
259	HIV infection is associated with higher levels of monocyte chemoattractant protein-1 and eotaxin among people with recent hepatitis C virus infection. <i>BMC Infectious Diseases</i> , 2016, 16, 241.	1.3	5
260	Extending a Helping Hand: Addressing Hepatitis C in Economic Migrants and Refugees. <i>Annals of Hepatology</i> , 2018, 17, 8-10.	0.6	5
261	Cost-effectiveness analysis of sofosbuvir and velpatasvir in chronic hepatitis C patients with decompensated cirrhosis. <i>Journal of Viral Hepatitis</i> , 2021, 28, 260-267.	1.0	5
262	Clinical significance of quantitative e antigen in a cohort of hepatitis B virus-infected children and adults in North America. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1042-1056.	1.0	5
263	Health care costs associated with hepatitis C virus infection in First Nations populations in Ontario: a retrospective matched cohort study. <i>CMAJ Open</i> , 2021, 9, E897-E906.	1.1	5
264	Risk of infections during interferon-based treatment in patients with chronic hepatitis C virus infection and advanced hepatic fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1057-1064.	1.4	4
265	Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1851-1859.	1.4	4
266	Pitfalls in measuring temporal trends for late diagnosis of viral hepatitis. <i>Journal of Hepatology</i> , 2019, 71, 1251-1254.	1.8	4
267	PS-139-Liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy. <i>Journal of Hepatology</i> , 2019, 70, e89.	1.8	4
268	Host Genetic Variant in CXCL16 May Be Associated With Hepatitis B Virus-Related Acute Liver Failure. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2019, 7, 477-479.e4.	2.3	4
269	Prevalence and predictors of complementary and alternative medicine modalities in patients with chronic hepatitis B. <i>Liver International</i> , 2019, 39, 1418-1427.	1.9	4
270	Validating viral hepatitis B and C diagnosis codes: a retrospective analysis using Ontario's health administrative data. <i>Canadian Journal of Public Health</i> , 2021, 112, 502-512.	1.1	4

#	ARTICLE	IF	CITATIONS
271	Impact of COVID-19 on Prescribing Trends of Direct-Acting Antivirals for the Treatment of Hepatitis C in Ontario, Canada. <i>American Journal of Gastroenterology</i> , 2021, 116, 1738-1740.	0.2	4
272	Non-surgical management of advanced hepatocellular carcinoma: A systematic review by Cancer Care Ontario. <i>Canadian Liver Journal</i> , 2021, 4, 257-274.	0.3	4
273	Preferences of Persons With or at Risk for Hepatitis C for Long-Acting Treatments. <i>Clinical Infectious Diseases</i> , 2022, 75, 3-10.	2.9	4
274	Determinants of Ligand Specificity and Functional Plasticity in Type I Interferon Signaling. <i>Frontiers in Immunology</i> , 2021, 12, 748423.	2.2	4
275	Vaccination at the forefront of the fight against hepatitis B and C. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 87-88.	8.2	4
276	Interferon responses and spontaneous HCV clearance: Is it all a matter of fat?. <i>Journal of Hepatology</i> , 2012, 57, 3-5.	1.8	3
277	Editorial Commentary: Sustained Virologic Response for Patients With Hepatitis C-Related Cirrhosis: A Major Milestone, but Not Quite a Cure. <i>Clinical Infectious Diseases</i> , 2013, 57, 237-239.	2.9	3
278	Management of HCV in Cirrhosis—a Rapidly Evolving Landscape. <i>Current Gastroenterology Reports</i> , 2015, 17, 443.	1.1	3
279	GARNET: High SVR Rates Following Eight-Week Treatment with Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir for Patients with HCV Genotype 1b Infection. <i>American Journal of Gastroenterology</i> , 2016, 111, S388.	0.2	3
280	One small SNP for receptor virus entry, one giant leap for hepatitis B?. <i>Gut</i> , 2016, 65, 1395-1397.	6.1	3
281	Inpatient viral diversity and treatment outcome in patients with genotype 3a hepatitis C virus infection on sofosbuvir-containing regimens. <i>Journal of Viral Hepatitis</i> , 2018, 25, 344-353.	1.0	3
282	The 7th Canadian Symposium on Hepatitis C Virus: “Toward Elimination of HCV: How to Get There” <i>Canadian Liver Journal</i> , 2018, 1, 139-152.	0.3	3
283	FRI-190-Incidence and predictors of flares after discontinuing nucleos (t) ide analogue therapy in HBeAg negative patients with chronic hepatitis B: Results from the randomized controlled STOP study. <i>Journal of Hepatology</i> , 2019, 70, e474.	1.8	3
284	Hepatitis C virus infection in mothers and children. <i>Canadian Liver Journal</i> , 2019, 2, 210-224.	0.3	3
285	Role of HVR1 sequence similarity in the cross-genotypic neutralization of HCV. <i>Virology Journal</i> , 2020, 17, 140.	1.4	3
286	Time Costs and Out-of-Pocket Costs in Patients With Chronic Hepatitis C in a Publicly Funded Health System. <i>Value in Health</i> , 2022, 25, 247-256.	0.1	3
287	HCV elimination: It will take a village and then some. <i>Journal of Hepatology</i> , 2020, 72, 601-603.	1.8	3
288	Hepatitis B reactivation in patients with solid tumors: A systematic review and meta-analysis. <i>Journal of Clinical Oncology</i> , 2016, 34, 138-138.	0.8	3

#	ARTICLE	IF	CITATIONS
289	Update on the Risk of Primary and Recurrent HCC With the Use of DAA Therapy for HCV Infection. <i>Gastroenterology and Hepatology</i> , 2019, 15, 303-306.	0.2	3
290	The mean attributable health care costs associated with hepatitis B virus in Ontario, Canada: A matched cohort study. <i>Canadian Liver Journal</i> , 2022, 5, 339-361.	0.3	3
291	Characteristics of Older Patients With Immunotolerant Chronic Hepatitis B Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1503-1512.e4.	2.4	3
292	HBV treatment in a patient who will be receiving immunosuppressive therapy. <i>Clinical Liver Disease</i> , 2013, 2, 34-37.	1.0	2
293	Hepatitis C virus infection. <i>Cmaj</i> , 2015, 187, 1159-1159.	0.9	2
294	Cure prevents more than transmission of hepatitis C virus. <i>Hepatology</i> , 2016, 64, 1003-1004.	3.6	2
295	Editorial: fenofibrate as secondâ€line therapy in high risk <scp>PBC</scp> â€“ more answers or more questions? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 649-650.	1.9	2
296	Overcoming the resistance to resistance testing: Collecting the data. <i>Liver International</i> , 2017, 37, 506-508.	1.9	2
297	PS-178-Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir: the SMART-C study. <i>Journal of Hepatology</i> , 2019, 70, e110.	1.8	2
298	THU-393-HCV infection in Canadian immigrants: Characteristics and treatment outcomes of the CANUHC cohort. <i>Journal of Hepatology</i> , 2019, 70, e328.	1.8	2
299	Hostâ€pathogen interactions in chronic HBV infection and transplantation of HCV-positive organs. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 77-78.	8.2	2
300	HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 259-261.	2.4	2
301	The 9th Canadian Symposium on Hepatitis C Virus: Advances in HCV research and treatment towards elimination. <i>Canadian Liver Journal</i> , 2021, 4, 59-71.	0.3	2
302	Hepatitis C virus infection in First Nations populations in Ontario from 2006 to 2014: a population-based retrospective cohort analysis. <i>CMAJ Open</i> , 2021, 9, E886-E896.	1.1	2
303	Sofosbuvir + Ribavirin With or Without Peginterferon Is Well-Tolerated and Associated with High SVR Rates: Integrated Results from 4 Phase 3 Trials in HCV Genotype 1-6. <i>American Journal of Gastroenterology</i> , 2013, 108, S123.	0.2	2
304	Birth cohort hepatitis C antibody prevalence in real-world screening settings in Ontario. <i>Canadian Liver Journal</i> , 2022, 5, 362-371.	0.3	2
305	Hepatitis B Biomarkers: Clinical Significance of the Old and the New. <i>Current Hepatitis Reports</i> , 2010, 9, 187-196.	0.3	1
306	Vascular Diseases of the Liver. , 2012, , 315-328.		1

#	ARTICLE	IF	CITATIONS
307	Commentary: non-haemodynamic effects of beta-blockers in cirrhosis - more than meets the eye?. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 652-652.	1.9	1
308	Commentary: what factors are important in diagnosing hepatic fibrosis?. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 545-546.	1.9	1
309	Does Eltrombopag Really ENABLE SVR?. <i>Gastroenterology</i> , 2014, 146, 339-342.	0.6	1
310	Clinical Trial Risk in Hepatitis C: Endpoint Selection and Drug Action. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2016, 2016, 1-7.	0.8	1
311	Protease inhibitors partially overcome the interferon nonresponse phenotype in patients with chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2016, 23, 340-347.	1.0	1
312	503 High SVR Rates in Patients with Genotype 4 Chronic Hepatitis C Infection and Compensated Cirrhosis With Ombitasvir/Paritaprevir/Ritonavir Co-Administered With Ribavirin (AGATE-I). <i>Gastroenterology</i> , 2016, 150, S1037.	0.6	1
313	812e The Use of Sofosbuvir and Velpatasvir is Associated With High Efficacy and Improvement in Patient-Reported Outcomes in Patients with Genotype 1, 2, 4, 5 and 6 Chronic Hepatitis C: Results from the ASTRAL-1 Clinical Trial. <i>Gastroenterology</i> , 2016, 150, S1267-S1268.	0.6	1
314	Safety and Efficacy of Sofosbuvir/Velpatasvir for the Treatment of Chronic Hepatitis C in Patients Aged 65 Years or Older: A Retrospective Analysis of Phase 3 Studies. <i>Gastroenterology</i> , 2017, 152, S1097.	0.6	1
315	Editorial: hepatitis C direct acting antiviral agents and the kidney” authors’ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 379-380.	1.9	1
316	Resolved HBV and anti-CD20 therapy. <i>Blood</i> , 2019, 133, 104-106.	0.6	1
317	Spontaneous Clearance After Relapse Following Direct-Acting Antiviral Treatment for Chronic HCV Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 19, 2398-2406.e1.	2.4	1
318	Letter to the Editor: Safety First: Favoring Prophylactic/Preemptive Over Delayed Treatment in D+/R+ Transplants. <i>Hepatology</i> , 2020, 72, 787-787.	3.6	1
319	Maintained virological suppression and renal function with reduced dose tenofovir disoproxil fumarate in renally impaired chronic hepatitis B patients. <i>Journal of Viral Hepatitis</i> , 2021, 28, 51-60.	1.0	1
320	The 8th Canadian Symposium on Hepatitis C virus: “Improving diagnosis and linkage to care” Canadian Liver Journal, 2020, 3, 3-14.	0.3	1
321	A collaborative approach to hepatitis C testing in two First Nations communities of Northwest Ontario. <i>Canadian Liver Journal</i> , 0, , .	0.3	1
322	The lighter side of myeloma: an easily overlooked diagnosis. <i>Gut</i> , 2005, 54, 1376-1376.	6.1	0
323	Noninvasive Tests of Fibrosis: To Get the Right Answers, We Need to Ask the Right Questions. <i>Hepatitis Monthly</i> , 2011, 11, .	0.1	0
324	HCV infection on-treatment viral kinetics: Do they still have a role?. <i>Clinical Liver Disease</i> , 2012, 1, 51-53.	1.0	0

#	ARTICLE	IF	CITATIONS
325	Tratamiento del VHB en pacientes que van a recibir terapia inmunosupresora. <i>Clinical Liver Disease</i> , 2013, 2, S28Å-S32Å.	1.0	0
326	Sigue desempeñando algún papel la cinética viral durante el tratamiento de la infección por el VHC?. <i>Clinical Liver Disease</i> , 2013, 2, S24Å-S27Å.	1.0	0
327	Reply to: "Evidence recommending antiviral therapy in hepatitis C". <i>Journal of Hepatology</i> , 2014, 60, 1102-1103.	1.8	0
328	Recommandations pour la prise en charge de l'infection par le virus de l'hépatite C chez les usagers de drogues par injection. <i>International Journal of Drug Policy</i> , 2015, , 101669.	1.6	0
329	Recomendaciones para el manejo de la infección por el virus de la hepatitis C entre usuarios de drogas por vía parenteral. <i>International Journal of Drug Policy</i> , 2015, , 101671.	1.6	0
330	751 Patient-Reported Outcomes in Chronic Hepatitis C Patients With Cirrhosis Treated With Ribavirin-Containing Regimens: Sofosbuvir/Velpatasvir and Ribavirin or Sofosbuvir and Ribavirin. <i>Gastroenterology</i> , 2016, 150, S1046.	0.6	0
331	Reply to J. Cabezas et al. <i>Journal of Clinical Oncology</i> , 2016, 34, 290-291.	0.8	0
332	Integrated Analysis of Controlled Clinical Trials Evaluating Efficacy and Safety of Sofosbuvir-Based Regimens in Chronic Hepatitis C Genotype 6 (HCV GT 6). <i>Gastroenterology</i> , 2017, 152, S1094.	0.6	0
333	Response to Cytoplasmic rods and rings in ribavirin and Cytoplasmic rods and rings in mycophenolic acid treatment.. <i>Liver International</i> , 2017, 37, 1743-1744.	1.9	0
334	The Newest Direct-Acting Antiviral Agents: the Final Chapter in DAA Development. <i>Current Hepatology Reports</i> , 2018, 17, 97-104.	0.4	0
335	Hepatitis B Reactivation in the DAA Era: Minding the Gap Between the Black Box and Clinical Practice. <i>Current Hepatology Reports</i> , 2018, 17, 444-450.	0.4	0
336	PS-056-Higher relapse and retreatment rates in patients who started as HBeAg positive than negative after stopping long-term nucleos(t)ide analogue therapy: results from the randomized controlled STOP study. <i>Journal of Hepatology</i> , 2019, 70, e34.	1.8	0
337	THU-305-Comparing perceptions of illness among patients with chronic liver disease. <i>Journal of Hepatology</i> , 2019, 70, e294-e295.	1.8	0
338	FRI-170-Real-world effectiveness and renal safety of tenofovir alafenamide fumarate among chronic hepatitis B patients in Canada. <i>Journal of Hepatology</i> , 2019, 70, e463-e464.	1.8	0
339	FRI-226-Modeling early viral kinetics during observed HCV acute infection in post lung transplantation recipients. <i>Journal of Hepatology</i> , 2019, 70, e494-e495.	1.8	0
340	FRI-257-Making OraQuick quicker: A hepatitis C point-of-care assay reduced to five minutes for viremic individuals. <i>Journal of Hepatology</i> , 2019, 70, e507.	1.8	0
341	PS-189-Toronto HCC risk index and albumin predict low risk of hepatocellular carcinoma after sustained virological response in hepatitis C infection. <i>Journal of Hepatology</i> , 2019, 70, e116-e117.	1.8	0
342	THU-154-Low rate of hepatitis B reactivation among patients with chronic hepatitis C during direct acting antiviral therapy. <i>Journal of Hepatology</i> , 2019, 70, e229-e230.	1.8	0

#	ARTICLE	IF	CITATIONS
343	Controversies in Treating Chronic Hepatitis B Virus Infection. Clinics in Liver Disease, 2021, 25, 805-816.	1.0	0
344	Screening for hepatitis B virus (HBV) prior to chemotherapy: A cost-effectiveness analysis.. Journal of Clinical Oncology, 2011, 29, 6059-6059.	0.8	0
345	Hepatitis B reactivation in patients with lymphoma: A meta-analysis.. Journal of Clinical Oncology, 2013, 31, 228-228.	0.8	0
346	An electronic prompt prior to myelosuppressive therapy to improve hepatitis B virus screening.. Journal of Clinical Oncology, 2014, 32, 6627-6627.	0.8	0
347	Hepatitis B virus screening before adjuvant chemotherapy in patients with early stage breast cancer: A cost-effectiveness analysis.. Journal of Clinical Oncology, 2015, 33, 6617-6617.	0.8	0
348	Implications of Manganese in Chronic acquired hepatocerebral degeneration. Annals of Hepatology, 2018, 17, 0-10.	0.6	0
349	Hepatitis C models of care: approaches to elimination. Canadian Liver Journal, 2020, 3, 165-176.	0.3	0
350	Characterization of HCV-infected people who inject drugs (PWID) in the setting of clinical care in Canada (CAPICA): A retrospective study. Canadian Liver Journal, 2020, 3, 358-371.	0.3	0
351	An update from the Canadian Association for the Study of the Liver on the management of liver disease during the COVID-19 pandemic. Canadian Liver Journal, 2020, 3, 309-321.	0.3	0
352	A tribute to Dr Saya Victor Feinman. Canadian Liver Journal, 0, , .	0.3	0
353	Successful use of a hepatitis C viremic donor in pediatric bilateral lobar lung transplantation. JTCVS Techniques, 2022, , .	0.2	0
354	Practical Implementation of Universal Hepatitis B Virus Screening for Patients With Cancer. JCO Oncology Practice, 0, , .	1.4	0